Skip to main content

Table 2 Demographic and clinicopathological variables of 330 patients with operated stage III colon cancer in the standard, modified and unfinished XELOX group

From: Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Variables

Standard XELOX

(n = 126, %)

Modified XELOX

(n = 84, %)

Unfinished XELOX

(n = 120, %)

P value 1

P value 2

Age (years)

   

0.762

0.454

 ≤ 60

85 (67.5)

59 (70.2)

78 (65.0)

  

 > 60

41 (32.5)

25 (29.8)

42 (35.0)

  

Gender

   

1.000

0.386

 Male

69 (54.8)

46 (54.8)

74 (61.7)

  

 Female

57 (45.2)

38 (45.2)

46 (38.3)

  

BMI (kg/m2)

   

0.371

0.439

 < 18.5

12 (9.5)

6 (7.1)

14 (11.7)

  

 18.5–25.0

83 (65.9)

63 (75.0)

81 (67.5)

  

 > 25.0

31 (24.6)

15 (17.9)

25 (20.8)

  

Tumor size (cm)

   

0.945

0.885

 ≤ 4

77 (61.1)

52 (61.9)

73 (60.8)

  

 > 4

49 (38.9)

32 (38.1)

47 (39.2)

  

Tumor location

   

0.382

0.567

 Right-sided colon

43 (34.1)

34 (40.5)

54 (45.0)

  

 Left-sided colon

83 (65.9)

50 (59.5)

66 (55.0)

  

Tumor differentiation

   

0.751

0.536

 Well/moderately differentiated

91 (72.2)

63 (75.0)

84 (70.0)

  

 Poor/undifferentiated

35 (27.8)

21 (25.0)

36 (30.0)

  

T stage

   

< 0.001

< 0.001

 T1–2

7 (5.6)

1 (1.2)

8 (6.7)

  

 T3

72 (57.1)

23 (27.4)

61 (50.8)

  

 T4

47 (37.3)

60 (71.4)

51 (42.5)

  

Numbers of resected lymph nodes

   

0.145

0.433

 < 12

27 (21.4)

26 (31.0)

31 (25.8)

  

 ≥ 12

99 (78.6)

58 (69.0)

89 (74.2)

  

N stage

   

0.541

0.438

 N1

90 (71.4)

56 (66.7)

87 (72.5)

  

 N2

36 (28.6)

28 (33.3)

33 (27.5)

  

Preoperative serum CEA (ng/mL)

   

0.063

0.657

 ≤ 5

67 (53.2)

56 (66.7)

76 (63.3)

  

 > 5

59 (46.8)

28 (33.3)

44 (36.7)

  

Preoperative serum CA19-9 (U/mL)

   

0.275

0.092

 ≤ 24

86 (68.3)

64 (76.2)

78 (65.0)

  

 > 24

40 (31.7)

20 (23.8)

42 (35.0)

  

Risk stratification

   

0.002

0.008

 Low risk

58 (46.0)

21 (25.0)

52 (43.3)

  

 High risk

68 (54.0)

63 (75.0)

68 (56.7)

  
  1. XELOX oxaliplatin and capecitabine regimen, BMI body mass index, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9
  2. Right-sided colon cancer included the cecum, ascending colon, hepatic flexure, and transverse colon cancer, whereas left-sided colon cancer included the splenic flexure, descending colon, and sigmoid colon cancer. P value 1 is the result of comparing the standard XELOX regimen group with the modified XELOX regimen group. P value 2 is the result of comparing the unfinished XELOX regimen with the modified XELOX regimen group
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us